AIM: To compare photodynamic therapy (PDT) with PDT associated with systemic steroids (SS) for the control of juxta/subfoveal idiopathic choroidal neovascularisation (ICNV). METHODS:Patients with juxta/subfoveal ICNV were randomised and then treated. Visual gain and loss were defined as improvement in or worsening for two or more lines of best-corrected visual acuity (BCVA), respectively. Choroidal neovascularisation size after treatment was classified as "increased" and "reduced" if it was increased or reduced by >200 microm(2), respectively. RESULTS:10 patients were treated with PDT, 10 with SS followed by PDT. The median follow-up time was 22 and 21 months for the "steroid+PDT group" and the "PDT group", respectively. At 1 year, in the PDT group, five patients had stable/improved BCVA, and five became worse; the mean number of PDT was 2.3; in the steroid+PDT group, all patients were stable/improved and the mean number of PDT was 1.2. The difference between the two groups was significant (p<0.05). At 1 year, the ICNV size after treatment was better in the steroid+PDT group than in the PDT group (p<0.05). CONCLUSION: The use of SS before PDT has shown better BCVA outcome than PDT alone (p<0.05), reducing the mean number of PDT applications (1.2 vs 2.3, respectively), with smaller scar size.
RCT Entities:
AIM: To compare photodynamic therapy (PDT) with PDT associated with systemic steroids (SS) for the control of juxta/subfoveal idiopathic choroidal neovascularisation (ICNV). METHODS:Patients with juxta/subfoveal ICNV were randomised and then treated. Visual gain and loss were defined as improvement in or worsening for two or more lines of best-corrected visual acuity (BCVA), respectively. Choroidal neovascularisation size after treatment was classified as "increased" and "reduced" if it was increased or reduced by >200 microm(2), respectively. RESULTS: 10 patients were treated with PDT, 10 with SS followed by PDT. The median follow-up time was 22 and 21 months for the "steroid+PDT group" and the "PDT group", respectively. At 1 year, in the PDT group, five patients had stable/improved BCVA, and five became worse; the mean number of PDT was 2.3; in the steroid+PDT group, all patients were stable/improved and the mean number of PDT was 1.2. The difference between the two groups was significant (p<0.05). At 1 year, the ICNV size after treatment was better in the steroid+PDT group than in the PDT group (p<0.05). CONCLUSION: The use of SS before PDT has shown better BCVA outcome than PDT alone (p<0.05), reducing the mean number of PDT applications (1.2 vs 2.3, respectively), with smaller scar size.
Authors: Diego G Espinosa-Heidmann; Ivan J Suner; Eleut P Hernandez; Dagoberto Monroy; Karl G Csaky; Scott W Cousins Journal: Invest Ophthalmol Vis Sci Date: 2003-08 Impact factor: 4.799
Authors: Richard F Spaide; Melissa L Martin; Jason Slakter; Lawrence A Yannuzzi; John Sorenson; David R Guyer; K Bailey Freund Journal: Am J Ophthalmol Date: 2002-07 Impact factor: 5.258
Authors: Wai-Man Chan; Dennis S C Lam; Tak-Hung Wong; Timothy Y Y Lai; Alvin K H Kwok; Barbara S M Tam; Kenneth K W Li Journal: Ophthalmology Date: 2003-12 Impact factor: 12.079
Authors: Narendra Dhingra; Susan Kelly; Mohammed A Majid; Claire B Bailey; Andrew D Dick Journal: Indian J Ophthalmol Date: 2010 Jan-Feb Impact factor: 1.848